Quantify structural exposure on any sourcing lane. HHI, top-3 exporter share, active-exporter count. The first risk-check before any API RFQ.
Type the molecule, origin country, and destination country. Works for API, FDF, biosimilar, and intermediates lanes.
The AI agent pulls customs, joins inspections and regulatory data, applies counterparty anonymisation, and returns the four headline KPIs in the chat.
Citation-anchored brief with KPIs, time series, anonymised exporter list, and a one-click handoff to the dual-source workflow.
Track HHI quarter on quarter. Surfaces concentration changes before any one supplier disrupts.
Run it before issuing an RFQ. A concentrated lane is a different procurement plan than a competitive one.
HHI ≥ 0.40 across two consecutive quarters triggers the dual-source candidate workflow with parameters pre-filled.
Counterparty identities are aggregated at the threshold required by the trade-data disclaimer. Lane-level only.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Eighteen molecule-lanes from the live warehouse · highest-value lane per molecule, 2024 · HHI on the 0 to 1 scale, four DOJ zones.
The Herfindahl-Hirschman Index is a 0-to-1 measure of supplier concentration on a sourcing lane, where 1 is a single-source monopoly. PharmaDB computes it on every (molecule, origin country, destination country) triple in the warehouse and surfaces it as the first risk-check before any sourcing decision. The view that backs this page is lane_competitiveness; the source table is molecule_country_flow. Refresh cadence is weekly.
The Herfindahl-Hirschman Index runs 0 to 1. PharmaDB applies the US DOJ horizontal-merger threshold: above 0.40 is structurally concentrated, above 0.60 is near-monopoly, below 0.25 is competitive.
Sum of squared exporter shares on the molecule-lane for the shipment year. Shares come from declared customs values. Exporters with under three shipments are excluded as noise. The view that backs the page is `lane_competitiveness`.
Identities are aggregated and anonymised at the threshold required by the trade-data disclaimer. The product never surfaces named buyer-to-seller transaction listings. Only lane-level aggregates.
Once a lane crosses 0.40 HHI for two quarters, qualify a second exporter with at least 20% unutilised capacity, an active regulatory dossier for the destination, and a clean recent inspection. The companion analysis is Dual-source candidate discovery.
Yes. The warehouse currently covers thousands of molecule-lane triples across India-out and emerging China-out flows. The largest origin coverage is India because India represents the dominant share of observable global API trade.
Trade aggregates refresh weekly. Inspection overlays refresh weekly. The catalog row carries a last-computed timestamp for every lane snapshot, surfaced on every result page.
Yes. The same methodology applies to API, FDF, biosimilars, and intermediates. The trastuzumab example above is a biosimilar lane. FDF lanes typically add regulatory layers (local marketing authorisation, ANVISA registration) as separate columns on the result.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.